HAS2 and ovarian carcinoma: At the molecular level, we evaluated basal expression levels of the HA axis in a panel of ovarian cancer cell lines and compared control ovarian cancer cells and HAS2 knockdown cells regarding gene expression of HAS1-3 and HYAL2-3, CD44, RHAMM and versican by qPCR.